18:46 , Feb 15, 2019 |  BC Week In Review  |  Financial News

TCR2 raises $75M in IPO

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced Feb. 13. The immuno-oncology company priced 5 million shares at $15, the midpoint of its proposed range of $14-$16. The price valued TCR2 at...
05:02 , Feb 14, 2019 |  BC Extra  |  Financial News

TCR2 prices $75M IPO at midpoint

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced late Wednesday. The company added $0.07 to $15.07 in its first day of trading Thursday. The immuno-oncology company priced 5 million shares at $15,...
23:22 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched on Feb. 7 with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first...
21:56 , Feb 7, 2019 |  BC Extra  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched Thursday with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first company exclusively...
18:58 , Feb 1, 2019 |  BioCentury  |  Finance

Discovering Dewpoint's protein organizers

An experienced team and a drug discovery platform targeting biomolecular condensates enabled Dewpoint Therapeutics to raise $60 million in a series A round led by founding investor Polaris Partners. Samsara BioCapital, 6 Dimensions Capital, EcoR1...
01:20 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Dewpoint launches with $60M series A to target biomolecular condensates

Dewpoint Therapeutics (Cambridge, Mass.) launched Jan. 30 with a $60 million series A round to fund development of its therapies targeting biomolecular condensates. Condensates are cellular organelles that concentrate and organize proteins and nucleic acids,...
14:01 , Jan 30, 2019 |  BC Extra  |  Financial News

Dewpoint launches with $60M series A to target biomolecular condensates

Dewpoint Therapeutics (Cambridge, Mass.) launched Wednesday with a $60 million series A round to fund development of its therapies targeting biomolecular condensates. Condensates are cellular organelles that concentrate and organize proteins and nucleic acids, which...
04:19 , Jan 4, 2019 |  BC Week In Review  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic in 2019, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Dec. 28 to raise $100 million in an IPO on NASDAQ. TCR2...
22:56 , Dec 28, 2018 |  BC Extra  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic next year, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Friday to raise $100 million in an IPO on NASDAQ. TCR2 is...
22:57 , Nov 30, 2018 |  BioCentury  |  Finance

Global Dimensions

6 Dimensions Capital has invested in at least nine U.S. biotechs this year out of its inaugural U.S. dollar fund, and the pace is expected to continue. Those investments have caught the eye of the...